Results 101 to 110 of about 25,087 (209)
International Journal of Cancer, Volume 158, Issue 7, Page 1836-1845, 1 April 2026.What's new? Patients with mantle cell lymphoma showing disease progression within 24 months of primary treatment have worse prognosis than patients with later progression. This population‐based study suggests that although early relapse is especially serious, disease progression more than 6 years after treatment still leads to worse survival than the ...
Sara Ekberg +5 more
wiley +1 more source
Extramedullary Disease—Achilles Heel in Myeloma?
American Journal of Hematology, Volume 101, Issue 3, Page 521-536, March 2026.ABSTRACT Despite advances in therapy, extramedullary disease (EMD) remains an aggressive form of multiple myeloma associated with poor outcomes. Patients with true EMD, in which plasmacytomas have become completely independent of bone, have a particularly poor prognosis. The pathogenesis of EMD is driven by complex mechanisms involving loss of adhesion
Shaji Kumar +7 more
wiley +1 more source
npj Precision OncologyThe efficacy and safety of venetoclax in newly diagnosed pediatric acute myeloid leukemia (AML) are not well-established as they are in adults. Children newly diagnosed with AML were recommended for induction therapy with venetoclax and chemotherapy or ...
Xiaojia Wen +20 more
doaj +1 more source
Infections in Chronic Lymphocytic Leukemia: Evolving Risks and Prevention Strategies
European Journal of Haematology, Volume 116, Issue 3, Page 204-214, March 2026.ABSTRACT Infections remain a leading cause of morbidity and mortality in patients with chronic lymphocytic leukemia (CLL), reflecting both intrinsic immune dysfunction and therapy‐related immunosuppression. The pathogenesis of immunodeficiency in CLL is multifactorial: neoplastic B cells impair humoral immunity, T cells are functionally exhausted, and ...
Enrica Antonia Martino +10 more
wiley +1 more source
Venetoclax efficacy on acute myeloid leukemia is enhanced by the combination with butyrate
Scientific ReportsVenetoclax has been approved recently for treatment of Acute myeloid leukemia (AML). Venetoclax is a BH3-mimetic and induces apoptosis via Bcl-2 inhibition. However, venetoclax’s effect is still restrictive and a novel strategy is needed.
Renshi Kawakatsu +3 more
doaj +1 more source
Exploring the synergy between telomere length and genomic complexity in CLL
British Journal of Haematology, EarlyView.
Silvia Ramos‐Campoy +19 more
wiley +1 more source
A Riboflavin‐Derived Flavinium Salt Mediates Chemoselective Methylation Reactions
Chemistry – A European Journal, Volume 32, Issue 5, 2 February 2026.A two‐component methylation protocol was developed, where the active flavin mediator can be recycled in a single step. Crystallographic data and NMR spectroscopy support the mechanistic proposal, while chemoselective methylation was observed for a broad range of biologically relevant substrates. ABSTRACT Selective methylation is among the most relevant
Tim Langschwager +3 more
wiley +1 more source
Cost of Serious Infections in Chronic Lymphocytic Leukemia
Cancer Medicine, Volume 15, Issue 2, February 2026.ABSTRACT Background The economic burden of chronic lymphocytic leukemia (CLL) is high, and is projected to increase with the introduction of new targeted treatments and improved survival. These high costs are not only associated with anticancer treatment, but also with the treatment and prevention of CLL symptoms and adverse events.
Sara Carrillo de Albornoz +5 more
wiley +1 more source
Blood Cancer JournalVenetoclax showed promising activity in a small phase II trial in relapsed/refractory Waldenström macroglobulinemia (WM). To report the clinical activity of venetoclax and prognostic factors associated with outcomes in a larger cohort, we retrospectively
Y. Sawalha +19 more
doaj +1 more source